VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Hammers on Immunotherapy Combinations in Kidney Cancer

Hans J. Hammers, MD, PhD
Published: Thursday, Sep 07, 2017



Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses combinations with immunotherapy being investigated for patients with kidney cancer.

Since nivolumab (Opdivo) has been approved, it has changed the treatment landscape for patients with kidney cancer, states Hammers. However, ongoing studies have been looking to combine nivolumab with other agents to increase the response.

Combining nivolumab with VEGF inhibitors is an area that has shown particular promise, explains Hammers. The trials investigating these combinations have shown encouraging data.



Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses combinations with immunotherapy being investigated for patients with kidney cancer.

Since nivolumab (Opdivo) has been approved, it has changed the treatment landscape for patients with kidney cancer, states Hammers. However, ongoing studies have been looking to combine nivolumab with other agents to increase the response.

Combining nivolumab with VEGF inhibitors is an area that has shown particular promise, explains Hammers. The trials investigating these combinations have shown encouraging data.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x